Balyasny Asset Management
PTX

Balyasny Asset Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Balyasny Asset Management’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,170
Closed -$5K – 1452
2016
Q2 		$5K Buy
+1,170
New +$7.64K ﹤0.01% 1127
2015
Q4 		– Sell
-3,680
Closed -$116K – 1609
2015
Q3 		$116K Buy
+3,680
New +$176K ﹤0.01% 1062

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Balyasny Asset Management's PTX Position: Q3 2016 in Review

Balyasny Asset Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q3 2016, closing a stake of 1,170 shares — an estimated $5K sold.

Balyasny Asset Management first reported a position in PTX in Q3 2015 and held it in 2 quarters. The position peaked at $116K in Q3 2015. 48 funds tracked by Wall St. Rank hold PTX as of Q3 2016.

  • Balyasny Asset Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q3 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 1,170 Pernix Therapeutics Holdings, Inc. shares in Q3 2016, an estimated $5K.
  • Balyasny Asset Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2015 and held it in 2 quarters.
  • Balyasny Asset Management's Pernix Therapeutics Holdings, Inc. position peaked at $116K in Q3 2015.
  • 48 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q3 2016.

Based on Balyasny Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.